; (ii) threats that consistently exist or continually circulate and have significant potential to become a pandemic, such as pandemic influenza, which may include the advanced research and development, manufacturing, and appropriate stockpiling of qualified pandemic or epidemic products, and products, technologies, or processes to support the advanced research and development of such countermeasures (including multiuse platform technologies for diagnostics, vaccines, and therapeutics; virus seeds; clinical trial lots; novel virus strains; and antigen and adjuvant material); and (iii) threats that may result primarily or secondarily from a chemical, biological, radiological, or nuclear agent, or emerging infectious disease, and which may present increased treatment complications such as the occurrence of resistance to available countermeasures or potential countermeasures, including antimicrobial resistant pathogens. . (b) Transaction authorities Section 319L(c)(5)(A) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(5)(A)) is amended— (1) by amending clause (i) to read as follows: (i) In general The Secretary shall have the authority to engage in transactions other than a contract, grant, or cooperative agreement with respect to projects under this section. ; and (2) in clause (ii)— (A) by amending subclause (I) to read as follows: (I) To the maximum extent practicable, competitive procedures shall be used when entering into agreements to carry out projects under this section. ; and (B) in subclause (II), by striking $20,000,000 and inserting $100,000,000 . (c) Pandemic influenza program Section 319L of the Public Health Service Act ( 42 U.S.C. 247d–7e ) is amended— (1) by redesignating subsections (d) through (f) as subsections (f) through (h), respectively